Evolution of Respiratory Function in Lung Transplant Patients With Moderate to Severe Covid-19 Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-04

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The SARS-Cov-2 infection pandemic has caused a large number of acute respiratory failures and deaths across the world. Certain factors have been identified as associated with a higher risk of developing a severe form and dying. Immunosuppression has been identified as a risk factor for progressing to a severe form.

Lung transplant patients were particularly vulnerable during this period, with a high frequency of respiratory compromise, sometimes progressing towards acute respiratory distress syndrome and, at a later stage, towards fibrotic forms. The impact of the infection on the immunological status of the patient and on the tolerance of the transplant have been little studied. The various treatments implemented during the pandemic have rapidly evolved (immunotherapy, vaccination, convalescent plasma transfusion, etc.) which may have modulated this risk. The evolution of respiratory function may be linked to the respiratory infection itself, or to the severity of respiratory damage during the infection. It is therefore relevant to compare patients with a moderate form of COVID-19 (non-intubated patients) to patients with severe forms, requiring invasive ventilation in intensive care. The evolution of respiratory function after infection has not yet been studied.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Solid Organ Transplant Recipients With SARS-CoV-2 French Registry

NCT04360707

SARS-CoV-2

UNKNOWN

Covid Vaccination in Liver Transplantation

NCT05079165

COVID-19

UNKNOWN

Optimization of Donor-Recipient Matching in Lung Transplantation

NCT05195853

Lung Transplant

UNKNOWN

Immunological Follow-up After SARS CoV2 Vaccination in Kidney Transplant Recipients

NCT04757883

Kidney Transplant Recipients

TERMINATED

Surveillance Study of Viral Infections Following Lung Transplantation

NCT00701922

Lung Transplantation Bronchiolitis Obliterans Epstein-Barr Virus Infections +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Respiratory Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient
* Lung transplant patient (monopulmonary or bipulmonary)
* Covid diagnosed by RT-PCR between March 1, 2020 and December 31, 2022
* Hospitalization at the University Hospitals of Strasbourg for COVID-19
* Patient followed in the context of their lung transplant at the University Hospitals of Strasbourg
* Absence of written opposition in the subject's medical file to the reuse of their data for scientific research purposes.